{"data":{"id":"us/42-cfr-428.404","jurisdiction":"us","citation":"42 CFR 428.404","heading":"Manufacturer access to Rebate Reports.","body":"(a) General. CMS will establish a method and process for a manufacturer of the Part D rebatable drug to:\n(1) Access the Rebate Report as set forth in §§ 428.401 and 428.402, including any report of a reconciled rebate amount as set forth in §§ 428.401 and 428.402;\n(2) Submit a Suggestion of Error as set forth in §§ 428.402(c) and 428.403; and\n(3) Pay a rebate amount as set forth in § 428.405.\n(b) [Reserved]","path":["Title 42—Public Health","CHAPTER IV—CENTERS FOR MEDICARE \u0026 MEDICAID SERVICES, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER B—MEDICARE PROGRAM","PART 428—MEDICARE PART D DRUG INFLATION REBATE PROGRAM","Subpart E—Reports of Rebate Amounts, Reconciliation, Suggestion of Error, and Payments"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-42.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:26:11Z","sha256":"039fd987fb937dbc74d9e5b981cf65d58e2e73bd85869634622976979019012d","source_id":"us-cfr","stale":true,"prev":"us/42-cfr-428.403","next":"us/42-cfr-428.405"},"notice":"GroundRules: Original legal text. Not legal advice."}